The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
Authors
Keywords
Chronic lymphocytic leukemia, Food effect, Ibrutinib, Pharmacokinetics, Tyrosine kinase inhibitor
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 5, Pages 907-916
Publisher
Springer Nature
Online
2015-02-27
DOI
10.1007/s00280-015-2708-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
- (2014) Eleonora Marostica et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
- (2012) A. Wiestner BLOOD
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- (2012) Joseph J. Buggy et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
- (2012) Adrian Wiestner JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- B-cell receptor signaling in chronic lymphocytic leukemia
- (2011) F. K. Stevenson et al. BLOOD
- Update on Therapy of Chronic Lymphocytic Leukemia
- (2011) John G. Gribben et al. JOURNAL OF CLINICAL ONCOLOGY
- Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
- (2010) S. P. Kang et al. CLINICAL CANCER RESEARCH
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Primary B Cell Immunodeficiencies: Comparisons and Contrasts
- (2009) Mary Ellen Conley et al. Annual Review of Immunology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started